Business
Glenmark Pharmaceuticals Inc., USA to launch 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial
Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce the upcoming launch1 of 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial. Glenmark's 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug, 8.4% Sodium Bicarbonate Injection, 50 mEq/50 mL (1 mEq/mL) of Abbott Laboratories Pharmaceutical Products Division (Abbott) NDA - 019443. Glenmark will begin
About this update from Glenmark Pharmaceuticals Limited
[{"type":"text","content":"ELMWOOD PARK, N.J., Nov. 4, 2025 /PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce the upcoming launch1 of 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial. Glenmark's 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug, 8.4% Sodium Bicarbonate Injection, 50 mEq/50 mL (1 mEq/mL) of Abbott Laboratories Pharmaceutical Products Division (Abbott) NDA - 019443. Glenmark will begin distribution in November 2025.","length":584,"tagName":"p"},{"type":"image","alt":"PRNE_Glenmark_Logo","displaySize":"","headline":null,"caption":"PRNE_Glenmark_Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":248,"url":"https://media.zenfs.com/en/prnewswire.com/665b8e82087cbb982ffe3ea107634a26"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QQPQSICzWHjx5eGgMRHVrQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQzNztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/665b8e82087cbb982ffe3ea107634a26","width":400,"height":248}}},{"type":"text","content":"According to IQVIA® sales data for the 12-month period ending August 2025, the 8.4% Sodium Bicarbonate Injection, 50 mEq/50 mL (1 mEq/mL) market2 achieved annual sales of approximately $63.8 million*.","length":205,"tagName":"p"},{"type":"text","content":"Commenting on the launch, Marc Kikuchi, President & Business Head, North America, said, "We are pleased to announce the expansion of our injectable portfolio to include the upcoming launch of 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial, which further reinforces our dedication to bring quality and affordable alternatives to market to patients in need."","length":408,"tagName":"p"},{"type":"text","content":"1Glenmark's 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial is only approved for the indication(s) listed in Glenmark's approved label.","length":175,"tagName":"p"},{"type":"text","content":"2Market includes brand and all available therapeutic equivalents. Note: IQVIA® data obtained by Glenmark is only available for all approved RLD indications. Glenmark's product is only approved for the indications listed in Glenmark's approved label and is n...